Arj Abbas, Ghaleh Takizadeh Zeinab, Gilassi Hamireza, Razavizadeh Mohsen
Department of Internal medicine, School of Medicine, Shahid Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
Department of Epidemiology and Biostatics, Health Faculty, Kashan University of Medical Sciences, Kashan, Iran.
Caspian J Intern Med. 2022 Winter;13(1):107-112. doi: 10.22088/cjim.13.1.107.
BACKGROUND: The aim of this study was to evaluate the relationship between the long-term use of PPI and hypomagnesemia in patients with gastroesophageal reflux disease. METHODS: This case control study was conducted on GERD patients with long-term use of proton pump inhibitor and patients with no history of gastroesophageal reflux and proton pump inhibitor referring to gastrointestinal clinic in 2019. Then concentration of serum magnesium (Mg) and potassium (K) were measured using atomic absorption spectrophotometer according to protocol. Other data were extracted from medical records. Statistical tests such as t-test, chi-square test and ONE WAY ANOVA were used for analysis of data. RESULTS: In the current study, 263 patients were classified into two groups (case: 132, control: 131). The mean level of potassium in case and control groups was 3.92±0.64 and 4.20±0.43, respectively (P=0.001). Moreover, the mean level of Mg in two groups was 2.03±0.36 and 2.09±0.52, respectively (P=0.24). In addition, significant difference was seen between serum level of K, regarding the type of proton pump inhibitor and duration of medication use (p<0.01). However, no significant difference was seen between serum levels of Mg, regarding the type of proton pump inhibitor such as pantoprazole and other drugs (p>0.05). CONCLUSION: Based on these results, long-term use of proton pump inhibitors is not associated with hypomagnesemia in GERD patients. However, long-term use of PPIs may reduce serum potassium levels in these patients. Therefore, periodic evaluation of serum Mg level in PPI-treated patients seems to be unnecessary.
背景:本研究旨在评估胃食管反流病患者长期使用质子泵抑制剂(PPI)与低镁血症之间的关系。 方法:本病例对照研究于2019年对长期使用质子泵抑制剂的胃食管反流病患者以及无胃食管反流和质子泵抑制剂使用史且前往胃肠科就诊的患者进行。然后按照方案使用原子吸收分光光度计测量血清镁(Mg)和钾(K)的浓度。其他数据从病历中提取。使用t检验、卡方检验和单因素方差分析等统计检验方法进行数据分析。 结果:在本研究中,263例患者被分为两组(病例组:132例,对照组:131例)。病例组和对照组的平均钾水平分别为3.92±0.64和4.20±0.43(P=0.001)。此外,两组的平均镁水平分别为2.03±0.36和2.09±0.52(P=0.24)。另外,根据质子泵抑制剂类型和用药持续时间,血清钾水平存在显著差异(p<0.01)。然而,对于泮托拉唑等质子泵抑制剂类型与其他药物,血清镁水平之间未见显著差异(p>0.05)。 结论:基于这些结果,长期使用质子泵抑制剂与胃食管反流病患者的低镁血症无关。然而,长期使用质子泵抑制剂可能会降低这些患者的血清钾水平。因此,对接受质子泵抑制剂治疗的患者定期评估血清镁水平似乎没有必要。
J Res Med Sci. 2020-11-26
Genomics Proteomics Bioinformatics. 2019-4-25
World J Gastroenterol. 2017-10-7
J Gastroenterol Hepatol. 2018-4-3
Aliment Pharmacol Ther. 2006-9-15
J Gastroenterol Hepatol. 2018-4-3
World J Nephrol. 2016-3-6
Ann Pharmacother. 2013-4-30
Kidney Int. 2013-1-16